Pharmerica Corporation (NYSE:PMC) was downgraded by equities research analysts at KeyCorp to an “overweight” rating in a note issued to investors on Tuesday.
Several other equities analysts have also commented on PMC. BidaskClub lowered shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. UBS AG reissued a “neutral” rating and issued a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a report on Thursday, August 3rd. Barrington Research downgraded Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a report on Thursday, August 3rd. Credit Suisse Group downgraded Pharmerica Corporation from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $29.00 to $29.25 in a report on Friday, August 4th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. Pharmerica Corporation has a consensus rating of “Hold” and an average price target of $28.83.
Shares of Pharmerica Corporation (NYSE:PMC) opened at 28.925 on Tuesday. Pharmerica Corporation has a 1-year low of $19.20 and a 1-year high of $29.10. The firm has a market capitalization of $900.17 million, a PE ratio of 39.194 and a beta of 0.92. The company has a 50-day moving average of $26.41 and a 200-day moving average of $24.88.
Pharmerica Corporation (NYSE:PMC) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.47. The company had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The firm’s revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.47 earnings per share. Equities research analysts predict that Pharmerica Corporation will post $1.92 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Pharmerica Corporation (PMC) Lowered to “Overweight” at KeyCorp” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://sportsperspectives.com/2017/08/10/pharmerica-corporation-pmc-lowered-to-overweight-at-keycorp.html.
Several large investors have recently bought and sold shares of PMC. BlackRock Inc. increased its stake in Pharmerica Corporation by 51,604.4% in the first quarter. BlackRock Inc. now owns 3,975,551 shares of the company’s stock valued at $93,027,000 after buying an additional 3,967,862 shares during the last quarter. Sessa Capital IM L.P. purchased a new stake in Pharmerica Corporation during the first quarter valued at $11,968,000. Royce & Associates LP increased its stake in Pharmerica Corporation by 966.5% in the second quarter. Royce & Associates LP now owns 426,600 shares of the company’s stock valued at $11,198,000 after buying an additional 386,600 shares during the last quarter. Victory Capital Management Inc. increased its stake in Pharmerica Corporation by 40.1% in the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock valued at $33,971,000 after buying an additional 370,266 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in Pharmerica Corporation by 61.3% in the first quarter. Nuveen Asset Management LLC now owns 863,975 shares of the company’s stock valued at $20,217,000 after buying an additional 328,257 shares during the last quarter. 92.84% of the stock is owned by institutional investors and hedge funds.
About Pharmerica Corporation
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.